Clinical Trial

An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy

Name: An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy — clinical trial record (NCT07238868)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.

Trial Details

NCT Number	NCT07238868
Lead Sponsor	Shanghai Zhimeng Biopharma, Inc.
Conditions	Focal Epilepsy
Enrollment	144 participants
Start Date	2025-08-14
Primary Completion	2029-01 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2025-11-20